6533b85ffe1ef96bd12c11bd
RESEARCH PRODUCT
Pharmacogenomics and the treatment of acute myeloid leukemia.
Juan Eduardo Megías-vericatSalvador F. AliñoSalvador F. AliñoJosé Luis PovedaPau MontesinosDavid Martínez-cuadrónMaría José HerreroMaría José HerreroMiguel A. SanzVirginia Bosósubject
0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBiologyMalignancy03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGeneticsmedicineSNPHumansGenetic variabilityPharmacologyChemotherapyPolymorphism GeneticMyeloid leukemiamedicine.diseaseLeukemia Myeloid Acute030104 developmental biologyPharmacogenetics030220 oncology & carcinogenesisPharmacogenomicsImmunologyCytarabineMolecular MedicinePharmacogeneticsmedicine.drugdescription
Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy that is primarily treated with combinations of cytarabine and anthracyclines. Although this scheme remains effective in most of the patients, variability of outcomes in patients has been partly related with their genetic variability. Several pharmacogenetic studies have analyzed the impact of polymorphisms in genes encoding transporters, metabolizers or molecular targets of chemotherapy agents. A systematic review on all eligible studies was carried out in order to estimate the effect of polymorphisms of anthracyclines and cytarabine pathways on efficacy and toxicity of AML treatment. Other emerging genes recently studied in AML, such as DNA repair genes, genes potentially related to chemotherapy response or AML prognosis, have also been included.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2016-07-01 | Pharmacogenomics |